Lung Cancer Home > Xalkori Uses
Xalkori is prescribed to treat non-small cell lung cancer that is in the late stages of the disease. Specifically, Xalkori is used for the treatment of this type of cancer in people who have a defect in a specific gene. It is approved only for people age 18 and older. At this time, there are no off-label uses for this chemotherapy medication.
What Is Xalkori Used For?Xalkori® (crizotinib) is a prescription medication approved to treat late-stage, non-small cell lung cancer. Late-stage cancer is cancer that has advanced or spread to other areas of the body (metastasized). Xalkori is only approved for use in people who have a defect in a specific gene known as the anaplastic lymphoma kinase (ALK) gene.
Lung cancer occurs when malignant (cancer) cells begin to grow in the tissues of the lung. There are two general types of lung cancer: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer is more common than small cell lung cancer. It also spreads more slowly.
In some people, an abnormal ALK gene is responsible for the development and growth of lung cancer cells. It is estimated that up to 7 percent of people with non-small cell lung cancer have the abnormal ALK gene. People with ALK-positive, non-small cell lung cancer are more likely to be younger and nonsmokers.
You will need to have a genetic test to determine if you have a defect in the ALK gene before beginning Xalkori treatment. In order to perform the test, your healthcare provider will take a small sample, or biopsy, from your lung cancer. The biopsy will then be examined for the presence of an abnormal ALK gene. If the gene is present, you may be a candidate for using Xalkori.